Herceptin

Breast Cancer

Herceptin is primarily used to treat HER2-positive breast cancer. This type of cancer has an overabundance of the human epidermal growth factor receptor 2 (HER2) protein, which promotes the growth of cancer cells. It is used in the following situations:

• Adjuvant Treatment: It may be used after surgery, chemotherapy, or radiation to help prevent the cancer from returning in patients with early-stage breast cancer.
• Metastatic Treatment: It is used to treat breast cancer that has spread to other parts of the body. In these cases, it may be used alone or combined with other chemotherapy drugs.

Stomach and Esophageal Cancer

Herceptin is also used to treat certain types of advanced stomach cancer, including:

• Metastatic Gastric Cancer: For patients with HER2-positive cancer of the stomach that has spread.
• Gastroesophageal Junction Adenocarcinoma: For cancer located where the esophagus meets the stomach.

Before starting treatment, a healthcare provider will perform a specific test on a tissue sample from the tumor to confirm that it is HER2-positive, as the medication is only effective for these specific types of cancer.

Targeting HER2 Proteins

Herceptin belongs to a class of drugs known as monoclonal antibodies. It is specifically designed to target the human epidermal growth factor receptor 2 (HER2) protein. In certain types of breast, stomach, and esophageal cancers, the cancer cells produce an abnormally high amount of this protein on their surface. These HER2 proteins send signals that tell the cancer cells to grow and divide rapidly.

How the Medication Acts on Cancer Cells

Herceptin works through several mechanisms to slow or stop the progression of the disease:

• Blocking growth signals: By attaching itself to the HER2 receptors on the surface of cancer cells, Herceptin blocks the signals that would otherwise tell the cells to multiply.
• Immune system activation: When the medication binds to the cancer cells, it may act as a marker that alerts the body's immune system. This helps immune cells identify, attack, and destroy the cancer cells.
• Disrupting cell signaling: By interfering with the HER2 protein, the drug disrupts the internal communication pathways that cancer cells rely on to survive and spread.

Because Herceptin specifically targets the HER2 protein, it is only effective in treating cancers that are confirmed to be HER2-positive through laboratory testing.

Common Side Effects

Many people experience mild to moderate side effects while receiving Herceptin. These often occur during or shortly after the infusion and may include:

• Fever and chills
• Nausea and vomiting
• Diarrhea
• Headache and dizziness
• Fatigue or weakness
• Muscle or joint pain
• Cough or shortness of breath
• Rash
• Difficulty sleeping (insomnia)
• Cold-like symptoms, such as a runny nose or sore throat

Serious Side Effects

Some side effects can be severe and require immediate medical attention. Contact your healthcare provider right away if you experience:

• Heart problems: Symptoms may include new or worsening shortness of breath, swelling in the ankles or feet, a persistent cough, or sudden weight gain.
• Infusion reactions: These typically occur during the first treatment and can include fever, chills, nausea, or breathing difficulties.
• Lung issues: Severe shortness of breath or difficulty breathing, which may indicate inflammation or fluid in the lungs.
• Low blood cell counts: A decrease in white blood cells can increase the risk of developing infections.

Boxed Warnings

Herceptin carries several boxed warnings, which are the most serious warnings issued by the FDA. These include:

• Cardiomyopathy: This medication can cause heart failure or a significant decrease in the heart's ability to pump blood.
• Infusion Reactions and Lung Problems: Severe and sometimes fatal reactions can occur during or shortly after the infusion.
• Embryo-Fetal Toxicity: Exposure during pregnancy can cause severe harm or death to a fetus.

Heart Health

Treatment with Herceptin can lead to heart damage, particularly a reduction in left ventricular ejection fraction (LVEF). The risk is significantly higher when Herceptin is used in combination with anthracycline-based chemotherapy. Healthcare providers typically monitor heart function before starting treatment and every few months during therapy.

Infusion and Lung Reactions

Serious infusion-related reactions may include low blood pressure, difficulty breathing, or swelling of the face and throat. Lung-related complications, such as inflammation of the lung tissue or fluid in the lungs, can also occur. These reactions are most common during the first dose but can happen at any time.

Pregnancy and Reproduction

Herceptin can cause low levels of amniotic fluid, which may lead to impaired lung development and skeletal abnormalities in the fetus. Individuals who can become pregnant are advised to use effective contraception during treatment and for at least seven months after the final dose.

Blood Cell Counts

When used with chemotherapy, Herceptin may increase the risk of low white blood cell counts (neutropenia). This can make the body more susceptible to infections.

Using Herceptin during pregnancy can cause serious harm to a developing fetus. Exposure to this medication has been linked to a condition called oligohydramnios, which is a significant decrease in the amount of amniotic fluid surrounding the baby. This lack of fluid can lead to severe complications, including:

• Underdeveloped lungs (pulmonary hypoplasia)
• Skeletal abnormalities
• Neonatal death

Healthcare providers typically perform a pregnancy test before starting treatment to ensure the patient is not pregnant. Individuals who can become pregnant should use effective contraception during treatment and for at least 7 months after the final dose. If a patient becomes pregnant while receiving Herceptin or within 7 months after the last dose, they should contact their healthcare provider immediately.

Breastfeeding

It is not known if Herceptin passes into human breast milk. Because many medications are excreted in milk and there is a potential for serious side effects in a nursing infant, patients should discuss with their healthcare team whether to stop breastfeeding or stop the medication. The decision usually depends on the clinical necessity of the drug for the mother.

Dosage Forms

Herceptin is available in the following form:

• Lyophilized Powder for Injection: This is a sterile, preservative-free powder contained in a vial. It is intended for intravenous use only after it has been properly prepared.

Because this medication is a powder, a healthcare provider must first reconstitute it with a liquid and then dilute it into an infusion bag. It is administered as an intravenous infusion, which means it is delivered slowly into a vein over a period of time. Herceptin is not available in oral forms, such as tablets or capsules, and cannot be self-administered.

FDA Approval and Indications

Herceptin was first approved by the U.S. Food and Drug Administration (FDA) in 1998. It is indicated for the treatment of HER2-overexpressing breast cancer, both in the adjuvant setting and for metastatic disease. It is also approved for the treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.

In addition to the original intravenous formulation, the FDA approved a subcutaneous formulation in 2019 for specific breast cancer indications.

Boxed Warnings

The FDA-approved labeling for Herceptin includes boxed warnings for several serious risks:

• Cardiomyopathy: Herceptin administration can result in subclinical and clinical cardiac failure. The risk is increased when used in combination with anthracyclines.
• Infusion Reactions and Pulmonary Toxicity: Severe and fatal infusion reactions and lung damage have been reported. These typically occur during or within 24 hours of administration.
• Embryo-Fetal Toxicity: Exposure to Herceptin during pregnancy can result in oligohydramnios (low amniotic fluid), which may lead to fetal renal failure, lung hypoplasia, and skeletal abnormalities.

Regulatory Status of Biosimilars

Multiple biosimilar products for trastuzumab have been approved by the FDA. These products are evaluated to ensure they are highly similar to the reference product, Herceptin, with no clinically meaningful differences in safety, purity, or potency.

Factors Influencing Cost

The total cost of Herceptin treatment varies significantly based on the specific treatment plan prescribed by a healthcare provider. Key factors include the dosage, the frequency of administration, and the total duration of the therapy.

Because Herceptin is an intravenous medication, it must be administered in a clinical setting, such as a hospital or infusion center. This means the total expense typically includes costs for the medication itself as well as facility fees and professional services for the administration.

Biosimilar Options

Herceptin is a biologic drug. There are several biosimilar versions of trastuzumab available on the market. Biosimilars are medications that are highly similar to the original biologic and have no clinically meaningful differences in safety or effectiveness. These options are often available at a lower cost than the brand-name drug.

Insurance Coverage and Assistance

Many insurance plans, including Medicare, cover Herceptin for its approved uses. Patients should check with their insurance provider to understand their specific coverage, including any requirements for prior authorization or out-of-pocket expenses like co-pays.

Financial assistance programs may be available through the drug manufacturer or non-profit organizations for patients who meet certain eligibility criteria. These programs can help reduce the cost of the medication for those without insurance or with high out-of-pocket costs.